BIOTRONIK Introduces First CE-Approved LBBAP-Enabled Defibrillator Platform, Advancing Precision Cardiac Rhythm Therapy
Published: 18 Feb 2026
Author: Precedence Research
BIOTRONIK has declared the commercial availability of its new innovative Acticor Sky and Rivacor Sky family. This is the introduction of the first-ever CE-approved high-voltage cardiac devices specifically aimed at the support of left bundle branch area pacing (LBBAP). These new generation implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy defibrillators (CRT-D) are a significant breakthrough in the management of cardiac rhythm. They provide a more physiological mode of electrical conduction, resembling that of the heart, more closely resembling the more physiological manner of cardiac electrical conduction. The devices are currently present in the CE-approved territories, which supports the inventive cardiovascular care technologies at BIOTRONIK.
This new family of devices also includes the proprietary DX technology by BIOTRONIK that improves the sensing of the atria. This improves the ability to detect arrhythmias and atrial fibrillation in particular, earlier and more accurately. Early diagnosis enables the clinician to put in place more effective interventions earlier and eliminate the chances of the development of complications like stroke or heart failure.
These technologies considerably improve patient comfort and quality of life without reducing therapeutic efficacy because they reduce shock delivery and increase rhythm control. Furthermore, the introduction of Acticor Sky and Rivacor Sky represents a pivotal shift in the future of cardiac rhythm management, thus creating immense opportunities for the company in the coming years.
Executives Statements
Dr. Anastasia Falagkari, Senior Attending Physician for Electrophysiology, University Hospital Frankfurt
“The device’s streamlined programming and diagnostics were immediately noticeable. Pacing in the left bundle branch area provides more physiological and synchronized heart contractions, which is exactly what we aim for in resynchronization therapy. CRT-DX technology allows a dual-lead CRT approach, contributing to a more efficient implantation procedure, and it is very likely to reduce complication risk in the future.”
Dr. Andreas Hecker, Chief Technology Officer, BIOTRONIK
“With Acticor and Rivacor Sky, we created a platform that elevates cardiac care. This new device family combines proven reliability with advanced algorithms to tailor therapy more precisely while simplifying workflows that support physicians in their daily work.”